Kamel Besseghir
Director/Board Member chez ONCODESIGN
Profil
Kamel Besseghir is currently an Independent Director at Oncodesign SA since 2014 and a Director at Oncodesign Precision Medicine SA since 2022.
Previously, he worked as the Chief Executive Officer at Debiopharm International SA from 1995 to 2012.
He also held positions as a Principal at Serono SA, The State University of New York, and the University of Lausanne.
Postes actifs de Kamel Besseghir
| Sociétés | Poste | Début |
|---|---|---|
| ONCODESIGN | Director/Board Member | 03/02/2014 |
| ONCODESIGN PRECISION MEDICINE | Director/Board Member | 14/09/2022 |
Anciens postes connus de Kamel Besseghir
| Sociétés | Poste | Fin |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | President | 01/01/2012 |
Serono SA
 Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Corporate Officer/Principal | - |
| The State University of New York | Corporate Officer/Principal | - |
| University of Lausanne | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ONCODESIGN PRECISION MEDICINE | Health Technology |
| Entreprise privées | 3 |
|---|---|
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
Oncodesign SA
 Oncodesign SA BiotechnologyHealth Technology Oncodesign SA is a biopharmaceutical company, which engages in the provision of solutions for the assessment and validation of anti-cancer therapies. It also offers services in pharmacology, pharmco-imaging, bio-analysis, bio-banking, translational bio-makers, and bio-decontamination. The firm operates through the following business units: Service, Biotech, and Artificial Intelligence. The company was founded by Philippe Genne and Eric Solary on January 17, 1995 and is headquartered in Dijon, France. | Health Technology |
